ImmuneRegen, Azopharma in Homspera Pact

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., has entered a strategic partnership agreement with Azopharma Product Development Group. Azopharma will perform research services to further develop ImmuneRegen’s lead drug candidate Homspera.

Azopharma will provide full development services to ImmuneRegen, including drug manufacturing, formulation development, and such preclinical services as IND-enabling toxicology and safety pharmacology studies.

Phil Meeks, chief executive officer of Azopharma Product Development Group, commented, “The potential benefits to humankind of ImmuneRegen’s lead compound has compelled Azopharma to undertake this strategic partnership. We are excited to undertake the development activities that will enable pre-clinical and clinical evaluation.”

The agreement, which is subject to the completion of work scope and budget by both parties and the negotiation and signing of a definitive agreement, is expected to close within 60 days, with work to begin immediately upon closing. ImmuneRegen intends to issue a certain amount of common stock and common stock purchase warrants to Azopharma, subject to the approval of the company’s board.

“We believe this partnership will provide the most expedited development of our lead candidate Homspera,” said ImmuneRegen chief executive officer Michael Wilhelm. “We feel privileged to be entering this relationship with Azopharma, given their extensive experience in swiftly developing similar products.”